Awareness and education of patients receiving bisphosphonates

Journal of Cranio-Maxillofacial Surgery

Volumn 40, Issue 3, 2012, Pages 277-282

  Bauer, Julia S ^a   Beck, Nina ^a   Kiefer, Julia ^a   Stockmann, Philipp ^a   Wichmann, Manfred ^a   Eitner, Stephan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bisphosphonate induced osteonecrosis of the jaw (BONJ); Bisphosphonates; Information level; Side effects

Indexed keywords

ALENDRON; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONEPHOS; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TEVANANTE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; AWARENESS; BONE PAIN; BREAST CANCER; CONSTIPATION; DENTAL CARIES; DENTAL SURGERY; DIARRHEA; DOCTOR PATIENT RELATION; DRUG POTENCY; ECZEMA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HEADACHE; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; JAW DISEASE; JAW OSTEONECROSIS; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEOPLASM; ORAL SURGERY; OSTEOPOROSIS; PATIENT INFORMATION; PATIENT PARTICIPATION; PRESCRIPTION; PROSTATE CANCER; QUESTIONNAIRE; RISK ASSESSMENT; SIDE EFFECT; TOOTH CALCULUS; VERTIGO; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; ARTHRALGIA; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DENTAL CARE; DENTIST-PATIENT RELATIONS; DENTISTS; DIPHOSPHONATES; DRUG LABELING; FEMALE; GASTROINTESTINAL DISEASES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH LITERACY; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84858709538     PISSN: 10105182     EISSN: 18784119     Source Type: Journal    
DOI: 10.1016/j.jcms.2011.04.011     Document Type: Article

References (39)

1. Abu-Id MH, Acil Y, Gottschalk J, Kreusch T: [Bisphosphonate-associated osteonecrosis of the jaw]. Mund Kiefer Gesichtschir 10: 73-81, 2006
2. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al: "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36: 95-103, 2008
3. Alons K, Kuijpers SC, de Jong E, van Merkesteyn JP: Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107: 1-7, 2009
4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587, 2005 (Pubitemid 46211499)
5. Bartl R, von Tresckow E, Bartl C: Bisphosphonate manual. 2006
6. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243-6249, 2006
7. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ: Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42: 848-860, 2008
8. Dannemann C, Gratz KW, Riener MO, Zwahlen RA: Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 40: 828-834, 2007 (Pubitemid 46386541)
9. Dannemann C, Gratz KW, Zwahlen RA: [Bisphosphonate-induced osteonecrosis of the jaws - a guide to diagnosis, therapy and prevention of BON in dental practice]. Schweiz Monatsschr Zahnmed 118: 113-123, 2008
10. Estefania FR, Ponte FR, guirre Urizar JM: Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal 11: 456-461, 2006
11. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, et al: Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112: 605-609, 2009
12. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al: Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32: 1123-1128, 2005 (Pubitemid 41499467)
13. Fleisch H: Development of bisphosphonates. Breast Cancer Res 4: 30-34, 2002
14. Fleisch H, Russell RG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262-1264, 1969
15. Francis MD, Russell RG, Fleisch H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264-1266, 1969
16. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al: Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 65: 1321-1327, 2007 (Pubitemid 46907400)
17. Grötz K, Kreusch T: [Dental care for patients during/after medication of bisposphonates (scientific statement of DGZMK, committee of maxillofacial surgery, DGMKG)]. Dtsch Zahnärztl Z 61: 510-513, 2006
18. Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D: Epidemiology, treatment and costs of osteoporosis in Germany - the BoneEVA Study. Osteoporos Int 18: 77-84, 2007 (Pubitemid 44885498)
19. Hewitt C, Farah CS: Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 36: 319-328, 2007 (Pubitemid 46889876)
20. Hoefert S, Eufinger H: [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. Mund Kiefer Gesichtschir 9: 233-238, 2005
21. Kademani D, Koka S, Lacy MQ, Rajkumar SV: Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81: 1100-1103, 2006 (Pubitemid 44175022)
22. Kyrgidis A, Triaridis S: Regular dental check-ups could be of benefit for patients receiving intravenous bisphosphonates. Regarding 'risks and benefits of bisphosphonates'. Br J Cancer 100: 670, 2009
23. Kyrgidis A, Vahtsevanos K: Osteonecrosis of the jaw in patients receiving oral bisphosphonates. Osteoporos Int 21: 535-536, 2010
24. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, et al: Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 14-21, 2006 (Pubitemid 44016120)
25. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A: Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 68: 107-110, 2010
26. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117, 2003
27. Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575, 2005 (Pubitemid 41525412)
28. Migliorati CA: Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21: 4253-4254, 2003
29. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa AM, et al: Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jawin patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49: 2156-2162, 2008
30. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P: A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29: 1548-1558, 2007 (Pubitemid 47500128)
31. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20: 137-145, 2009
32. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial. Cancer J 7: 377-387, 2001 (Pubitemid 33759002)
33. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67: 2-12, 2009
34. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a reviewof 63 cases. J Oral Maxillofac Surg 62: 527-534, 2004 (Pubitemid 38542516)
35. Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al: Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 68: 797-804, 2010
36. Schwartz HC: Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 62: 763-764, 2004
37. Starck WJ, Epker BN: Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10: 74-78, 1995
38. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al: Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 18: 449-460, 2010
39. Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San MJ, et al: The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20: 1303-1317, 2009